Cargando…
Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis
Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic is...
Autores principales: | Badra, Gamal, Waked, Imam, Selmi, Carlo, Saleh, Saleh M., El-Shaarawy, Ahmed, Lotfy, Mahmoud |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270744/ https://www.ncbi.nlm.nih.gov/pubmed/16603440 http://dx.doi.org/10.1080/17402520600557867 |
Ejemplares similares
-
Cross Reactive Cellular Immune Response to HCV Genotype 1 and 4 Antigens among Genotype 4 Exposed Subjects
por: Galal, Iman F., et al.
Publicado: (2014) -
Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018) -
Personalized medicine in rheumatology: the paradigm of serum autoantibodies
por: Sirotti, Silvia, et al.
Publicado: (2017) -
Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype
por: Danilau, Dzmitry, et al.
Publicado: (2017) -
Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α
por: Keppeke, Gerson Dierley, et al.
Publicado: (2012)